Immunicum AB Announces Hiring New Investor Relations Firm

Gothenburg, Sweden, March 14, 2016 - Immunicum AB (publ), striving to develop sophisticated, safe and efficient therapeutic cancer treatments with powerful and long lasting immune responses, today announced that the Company has engaged The Blueshirt Group to assist Immunicum in developing its communication and investor outreach program with the global financial community.

"Our strategy is to partner with The Blueshirt Group to help us expand our presence in the international investment community and communicate our increasing development efforts", said Jamal El-Mosleh, Chief Executive Officer of Immunicum. "We are looking forward to leveraging The Blueshirt Group's and Julie Silbe's extensive experience in working with healthcare, biotech and pharma companies as we enter the next stage of our Company's development."

"This is a great opportunity to work with an advancing biotech company in the cancer treatment space and we are excited to help the investment community better understand Immunicum's strategy and opportunity," said Julie Silber, Managing Director of the European office of The Blueshirt Group. "With the on-going announcements from the successes of the clinical trials, the potential market size and the positive results with liver cancer patients and kidney cancer patients, we expect that the interest from the financial community will continue to expand and we are delighted to be here as part of the Immunicum team."

For further information, please contact:

Julie Silber, Investor Relations
ir@immunicum.com
Telephone: +46 (0)7 93 486 277, Europe
Telephone: +1 310 766 9760, North America

About Immunicum AB (publ)

Immunicum AB (publ) is working to develop and advance cancer immune primers for the treatment of tumor diseases. A clinical phase II trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer in gastrointestinal stromal tumors (GIST). The Company's current lead project is INTUVAX, a cancer immune primer, developed for the treatment of solid tumors. Its active ingredient is activated white blood cells, so called dendritic cells, derived from healthy blood donors. Intratumoral injection of these cells is expected to lead to an inflammatory response which in turn leads to tumor-specific activation of the patient's cytotoxic T lymphocytes.

For more information, please visit www.immunicum.com

About The Blueshirt Group

The Blueshirt Group provides capital markets expertise and strategic financial and media relations counsel to growth companies and venture capital firms globally. Founded in 1999, the firm has earned its reputation as a leader in investor relations, financial communications, financial media relations and crisis management.

For more information, please visit www.blueshirtgroup.com.